Eli Lilly will tack on $450 million more to increase capacity in a diabetes drug plant in light of shortages; patients emailing and messaging medical providers online might be charged; 57% of adults in a recent survey think that the federal government should secure health care coverage for all Americans.
Eli Lilly Will Invest Extra $450 Million to Expand Diabetes Drug Plant
Eli Lilly and Co is planning to invest an added $450 million to its Research Triangle Park manufacturing location in North Carolina to keep up with the amplified demand for diabetes drugs dulaglutide (Trulicity) and tirzepatide (Mounjaro, according to Reuters. In January, the FDA included both drugs on its list of drug shortages. The company intends to double production of the incretin drug class by the end of 2023, which includes both medications.
More Providers Billing for Patient Emails, Portal Messages
Electronic health communication has started to cost some patients when they communicate with providers online through emails and patient portals, The New York Times reported. CMS created billing codes for reimbursement for portal messages before the pandemic, and some insurers have followed suit. Billable messages must meet certain criteria to be charged and can be at the discretion of the providing institution. Electronic messages grew during the pandemic, and some providers said the time to respond adds to their workday. Critics are concerned that this new initiative could decrease health equity and drive people away from care.
Survey Shows Most Adults Favor Some Type of Guaranteed Universal Health Care
The majority of adults surveyed—57%— think that the federal government should guarantee health care coverage for all Americans, but most are partial to a private health care system rather than one controlled by the government, The Hill reported. The Gallup survey findings were the highest vote in favor of universal health care since 2018. Mostly Democrats and 59% of independents were in favor of the idea; just 28% of Republicans were, showing the complexities of Americans’ positions in their desire for governmental health care coverage simultaneously with a private coverage system.
Key Elements Affect Willingness to Pay for Sleep Disturbance Treatment
Certain variables have been shown to have both positive and negative influences on the willingness to pay for sleep disturbance treatment, such as wealth, insurance coverage, quality of life, and age.
Read More
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
Amazon Introduces Prescription Drug Subscription Program for $5 Monthly Fee
Amazon’s announcement of a prescription subscription service that charges a flat monthly fee instead of offering discounts on each prescription fill represents the retail giant’s latest foray into the health care space.
Read More
The Importance of Tailored Care Management Programs for High-risk Patients
On this episode of Managed Care Cast, we speak with 2 authors of an article in the September issue of The American Journal of Managed Care®, which focused on the results of their evaluation of an intensive, community-based care management program for dual-eligible Medicaid ACO high-risk patients.
Listen
Telehealth Likely as Effective as In-Person Care for MDD
Patients were also more likely to stay in treatment longer when their care was delivered virtually, a new survey has found.
Read More
ACAAI Report Highlights AD, Allergy Care Disparities and Proposed Solutions
Following member surveys, expert interviews, and roundtable discussions, the American College of Allergy, Asthma, and Immunology (ACAAI) has released new recommendations for overcoming care disparities among those who have atopic dermatitis (AD) and food allergies.
Read More
2 Clarke Drive
Cranbury, NJ 08512
609-716-7777